Biocon Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 9:22 pm

Quick Insight

Biocon Ltd, a leading player in the pharmaceutical industry, currently trades at a price of 360 with a market capitalization of 48,164 Cr. The company's P/E ratio stands at 119, reflecting a premium valuation, while ROE and ROCE are at 4.76% and 6.25% respectively, indicating room for improvement in efficiency. With OPM at 24%, Biocon demonstrates strong operational performance. The distribution of shareholding is well-diversified among promoters (60.64%), FIIs (5.90%), DIIs (14.29%), and the public (18.90%), with a significant number of shareholders at 4,43,513. The company's healthy reserves of 21,044 Cr and manageable borrowings of ₹18,362 Cr contribute to a comfortable ICR of 4.27x and a modest P/BV of 1.60x. Overall, Biocon's financial metrics suggest a solid foundation for growth, but there is a need to enhance profitability and shareholder returns to unlock its full potential in the market.

Competitors of Biocon Ltd

All Competitor Stocks of Biocon Ltd

Quarterly Result

Last Updated: August 20, 2025, 12:45 pm

Below is a detailed analysis of the quarterly data for Biocon Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 3,942.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,417.00 Cr. (Mar 2025) to 3,942.00 Cr., marking a decrease of 475.00 Cr..
• For Expenses, as of Jun 2025, the value is 3,193.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3,339.00 Cr. (Mar 2025) to 3,193.00 Cr., marking a decrease of 146.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 749.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,078.00 Cr. (Mar 2025) to 749.00 Cr., marking a decrease of 329.00 Cr..
• For OPM %, as of Jun 2025, the value is 19.00%. The value appears to be declining and may need further review. It has decreased from 24.00% (Mar 2025) to 19.00%, marking a decrease of 5.00%.
• For Other Income, as of Jun 2025, the value is 80.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2025) to 80.00 Cr., marking an increase of 23.00 Cr..
• For Interest, as of Jun 2025, the value is 277.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 212.00 Cr. (Mar 2025) to 277.00 Cr., marking an increase of 65.00 Cr..
• For Depreciation, as of Jun 2025, the value is 455.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 436.00 Cr. (Mar 2025) to 455.00 Cr., marking an increase of 19.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 97.00 Cr.. The value appears to be declining and may need further review. It has decreased from 487.00 Cr. (Mar 2025) to 97.00 Cr., marking a decrease of 390.00 Cr..
• For Tax %, as of Jun 2025, the value is 8.00%. The value appears to be increasing, which may not be favorable. It has increased from 6.00% (Mar 2025) to 8.00%, marking an increase of 2.00%.
• For Net Profit, as of Jun 2025, the value is 89.00 Cr.. The value appears to be declining and may need further review. It has decreased from 459.00 Cr. (Mar 2025) to 89.00 Cr., marking a decrease of 370.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.23. The value appears to be declining and may need further review. It has decreased from 2.87 (Mar 2025) to 0.23, marking a decrease of 2.64.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:29 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 3:29 pm

Below is a detailed analysis of the balance sheet data for Biocon Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 600.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 600.00 Cr..
• For Reserves, as of Mar 2025, the value is 21,044.00 Cr.. The value appears strong and on an upward trend. It has increased from 19,183.00 Cr. (Mar 2024) to 21,044.00 Cr., marking an increase of 1,861.00 Cr..
• For Borrowings, as of Mar 2025, the value is 18,362.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 16,277.00 Cr. (Mar 2024) to 18,362.00 Cr., marking an increase of 2,085.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 18,534.00 Cr.. The value appears to be improving (decreasing). It has decreased from 19,693.00 Cr. (Mar 2024) to 18,534.00 Cr., marking a decrease of 1,159.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 58,540.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 55,753.00 Cr. (Mar 2024) to 58,540.00 Cr., marking an increase of 2,787.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 31,963.00 Cr.. The value appears strong and on an upward trend. It has increased from 30,644.00 Cr. (Mar 2024) to 31,963.00 Cr., marking an increase of 1,319.00 Cr..
• For CWIP, as of Mar 2025, the value is 8,508.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,993.00 Cr. (Mar 2024) to 8,508.00 Cr., marking an increase of 515.00 Cr..
• For Investments, as of Mar 2025, the value is 1,127.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,000.00 Cr. (Mar 2024) to 1,127.00 Cr., marking an increase of 127.00 Cr..
• For Other Assets, as of Mar 2025, the value is 16,941.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,117.00 Cr. (Mar 2024) to 16,941.00 Cr., marking an increase of 824.00 Cr..
• For Total Assets, as of Mar 2025, the value is 58,540.00 Cr.. The value appears strong and on an upward trend. It has increased from 55,753.00 Cr. (Mar 2024) to 58,540.00 Cr., marking an increase of 2,787.00 Cr..

Notably, the Reserves (21,044.00 Cr.) exceed the Borrowings (18,362.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Biocon Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 8.55. This value is within the healthy range. It has increased from 3.88 (Mar 23) to 8.55, marking an increase of 4.67.
• For Diluted EPS (Rs.), as of Mar 24, the value is 8.54. This value is within the healthy range. It has increased from 3.87 (Mar 23) to 8.54, marking an increase of 4.67.
• For Cash EPS (Rs.), as of Mar 24, the value is 24.58. This value is within the healthy range. It has increased from 16.02 (Mar 23) to 24.58, marking an increase of 8.56.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 210.51. It has increased from 187.31 (Mar 23) to 210.51, marking an increase of 23.20.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 210.52. It has increased from 187.31 (Mar 23) to 210.52, marking an increase of 23.21.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 122.90. It has increased from 93.07 (Mar 23) to 122.90, marking an increase of 29.83.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 34.68. This value is within the healthy range. It has increased from 24.05 (Mar 23) to 34.68, marking an increase of 10.63.
• For PBIT / Share (Rs.), as of Mar 24, the value is 21.62. This value is within the healthy range. It has increased from 14.78 (Mar 23) to 21.62, marking an increase of 6.84.
• For PBT / Share (Rs.), as of Mar 24, the value is 13.40. This value is within the healthy range. It has increased from 8.86 (Mar 23) to 13.40, marking an increase of 4.54.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 11.51. This value is within the healthy range. It has increased from 6.75 (Mar 23) to 11.51, marking an increase of 4.76.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 8.52. This value is within the healthy range. It has increased from 3.85 (Mar 23) to 8.52, marking an increase of 4.67.
• For PBDIT Margin (%), as of Mar 24, the value is 28.22. This value is within the healthy range. It has increased from 25.84 (Mar 23) to 28.22, marking an increase of 2.38.
• For PBIT Margin (%), as of Mar 24, the value is 17.58. This value is within the healthy range. It has increased from 15.88 (Mar 23) to 17.58, marking an increase of 1.70.
• For PBT Margin (%), as of Mar 24, the value is 10.90. This value is within the healthy range. It has increased from 9.52 (Mar 23) to 10.90, marking an increase of 1.38.
• For Net Profit Margin (%), as of Mar 24, the value is 9.36. This value is within the healthy range. It has increased from 7.24 (Mar 23) to 9.36, marking an increase of 2.12.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 6.92. This value is below the healthy minimum of 8. It has increased from 4.14 (Mar 23) to 6.92, marking an increase of 2.78.
• For Return on Networth / Equity (%), as of Mar 24, the value is 5.16. This value is below the healthy minimum of 15. It has increased from 2.58 (Mar 23) to 5.16, marking an increase of 2.58.
• For Return on Capital Employeed (%), as of Mar 24, the value is 6.37. This value is below the healthy minimum of 10. It has increased from 4.07 (Mar 23) to 6.37, marking an increase of 2.30.
• For Return On Assets (%), as of Mar 24, the value is 1.82. This value is below the healthy minimum of 5. It has increased from 0.88 (Mar 23) to 1.82, marking an increase of 0.94.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.65. This value is within the healthy range. It has decreased from 0.85 (Mar 23) to 0.65, marking a decrease of 0.20.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.79. This value is within the healthy range. It has decreased from 0.99 (Mar 23) to 0.79, marking a decrease of 0.20.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.27. It has decreased from 0.30 (Mar 23) to 0.27, marking a decrease of 0.03.
• For Current Ratio (X), as of Mar 24, the value is 0.98. This value is below the healthy minimum of 1.5. It has decreased from 1.45 (Mar 23) to 0.98, marking a decrease of 0.47.
• For Quick Ratio (X), as of Mar 24, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.95 (Mar 23) to 0.66, marking a decrease of 0.29.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.10. This value is below the healthy minimum of 4. It has increased from 0.97 (Mar 23) to 1.10, marking an increase of 0.13.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 17.61. This value is below the healthy minimum of 20. It has increased from 12.96 (Mar 23) to 17.61, marking an increase of 4.65.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 6.95. This value is below the healthy minimum of 20. It has increased from 3.80 (Mar 23) to 6.95, marking an increase of 3.15.
• For Earning Retention Ratio (%), as of Mar 24, the value is 82.39. This value exceeds the healthy maximum of 70. It has decreased from 87.04 (Mar 23) to 82.39, marking a decrease of 4.65.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 93.05. This value exceeds the healthy maximum of 70. It has decreased from 96.20 (Mar 23) to 93.05, marking a decrease of 3.15.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 4.27. This value is within the healthy range. It has decreased from 6.89 (Mar 23) to 4.27, marking a decrease of 2.62.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.43. This value is below the healthy minimum of 3. It has decreased from 3.63 (Mar 23) to 2.43, marking a decrease of 1.20.
• For Enterprise Value (Cr.), as of Mar 24, the value is 50,669.85. It has increased from 44,766.88 (Mar 23) to 50,669.85, marking an increase of 5,902.97.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 4.01 (Mar 23) to 3.43, marking a decrease of 0.58.
• For EV / EBITDA (X), as of Mar 24, the value is 12.17. This value is within the healthy range. It has decreased from 15.50 (Mar 23) to 12.17, marking a decrease of 3.33.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.15. This value is within the healthy range. It has decreased from 2.22 (Mar 23) to 2.15, marking a decrease of 0.07.
• For Retention Ratios (%), as of Mar 24, the value is 82.38. This value exceeds the healthy maximum of 70. It has decreased from 87.03 (Mar 23) to 82.38, marking a decrease of 4.65.
• For Price / BV (X), as of Mar 24, the value is 1.60. This value is within the healthy range. It has increased from 1.39 (Mar 23) to 1.60, marking an increase of 0.21.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.15. This value is within the healthy range. It has decreased from 2.22 (Mar 23) to 2.15, marking a decrease of 0.07.
• For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 23) to 0.03, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness